Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
Noosa News19 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General18 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News21 hours agoWomen’s Softball World Cup 2027 Redcliffe Brisbane
-
General21 hours agoMan dies at shopping centre car park at Charlestown following reports of assault